A number of challenges are associated with interpreting and utilizing genetic information, as discussed by Peter Salgo, MD, and Irwin W. Tischler, DO.
Dr Tischler explains that although a drug that targets a specific mutation may show benefit in a particular type of cancer, it is unclear whether the drug would be effective in other types of cancer. For example, drugs that target KRAS have shown efficacy in the treatment of patients with wild-type KRAS colorectal cancer. However, the KRAS mutation is present in other cancers, and it is unclear whether the KRAS mutation is the same across cancer types. For this reason, there is a need for research, despite financial concerns.
Cutbacks in Medicare reimbursement have affected research progress and have held back the pace of innovation in medical oncology, remarks Dr Tischler. However, he is hopeful that the restoration of the Cancer Care Act, currently in review by the US Congress, will address the reimbursement barrier.
Another challenge is the expense of newer drugs and technologies and the cost burden on the patient. Dr Tischler explains that high costs often dis-incentivize patients from receiving treatment. To reduce this financial burden and help patients receive the treatment they need, Dr Tischler explains, key stakeholders are now discussing an “all-encompassing” payment plan that would cover a patient’s entire course of treatment.
Watch our related Peer Exchange, Oncology Stakeholder Summit 2014: Evidence-Based Decisions to Improve Quality and Regulate Costs
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Medicaid, Medicare Policy Changes Could Lead to More Than 25,000 Additional Deaths, Study Says
April 30th 2024Researchers also estimated that more than 700,000 Americans with diabetes could lose insurance coverage if these proposed retractions are put into place, with some new policies already in effect.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen